SARS-CoV-2 targets MAVS for immune evasion.

Zotta, Alessia; Hooftman, Alexander; O'Neill, Luke A J

Zotta, Alessia; Hooftman, Alexander; O'Neill, Luke A J.

Zotta A; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland.
Hooftman A; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland.
O'Neill LAJ; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland. laoneill@tcd.ie.

Nat Cell Biol ; 23(7): 682-683, 2021 07.

Article in English | MEDLINE | ID: covidwho-1303774

Subject(s)

SARS-CoV-2/pathogenicity; Adaptor Proteins, Signal Transducing/genetics; Adaptor Proteins, Signal Transducing/metabolism; Angiotensin-Converting Enzyme 2/genetics; Angiotensin-Converting Enzyme 2/metabolism; Animals; COVID-19/immunology; Humans; Immune Evasion/physiology; Immunity, Innate/physiology; SARS-CoV-2/immunology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 Limits: Animals / Humans Language: English Journal: Nat Cell Biol Year: 2021 Document Type: Article Affiliation country: S41556-021-00712-y

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google